Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Dermatology
•
Atopic Dermatitis
How do you manage atopic dermatitis in patients who have failed dupilumab?
Related Questions
How does omalizumab play a role in the armamentarium of atopic dermatitis?
How do you weigh the risks/benefits of cytokine blockade (eg dupilumab) in pregnant patients?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
How do you counsel families of pediatric patients on methotrexate about live vaccine schedules?
Have you seen CD30+ lymphoproliferative skin lesions with Upadacitinib treatment of atopic dermatitis?
What is your approach for female patients with severe atopic dermatitis well controlled on Dupixent planning to conceive or already pregnant?
What is the longest interval that you have been able to stretch a biologic before losing efficacy?
How do you decide between IL-4/IL-13 blockade (dupixent) versus IL-13 blockade only (Adbry) as treatments for Atopic Dermatitis?
What criteria do you utilize in deciding between different jak inhibitors for atopic dermatitis?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?